CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Daptomycindrug
Likely dose
Daptomycin 6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00467272
NCT00467272Phase 2Completed
CompareCT.gov

Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Daptomycin in the Treatment of Catheter-Related Gram Positive Bloodstream Infections

M.D. Anderson Cancer Center·interventional·Posted Apr 30, 2007·Updated Feb 8, 2021

In Brief

A Phase 2 clinical trial evaluating Daptomycin for Bloodstream Infection. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Primary Objective: -Evaluate the clinical efficacy and safety of Daptomycin given for treatment of catheter-related bloodstream infections (CRBSI) due to gram positive bacteremia in the context of standard of care antimicrobial therapy consisting mainly of Vancomycin with or without initial treatment with beta lactam antibiotics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBloodstream Infection
CountriesUnited States
CollaboratorsCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 30, 2007
Enrollment StartMar 1, 2007
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 19.2 years ago

Interventions

Daptomycindrug

6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.